The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IACH MATH 2020 | CAR T-cell therapy for AML
Arnon Nagler, MD, Sheba Medical Center, Tel-Aviv, Israel, discusses the exciting field of CAR T-cell therapy in acute myeloid leukemia (AML). Although the success of CAR T-cell therapy in other fields has not been translated into treatment for AML, Prof. Nagler reveals that research is progressing and in the future CAR T-cells for AML might be a possible treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
